Rapid Bio has signed a memorandum of cooperation with the Skolkovo Foundation and investment company KAMA FLOW on the sidelines of the St Petersburg International Economic Forum (SPIEF-2025), in a move aimed at strengthening Russia’s capabilities in rapid diagnostics for socially significant diseases.
Under the agreement, the parties plan to pool their efforts to support the growth of Rapid Bio as a technological leader in point-of-care and rapid diagnostic solutions, including assistance with scaling development and manufacturing of domestic products.
The memorandum was signed by Anzhey Zhimbiyev, Chief Executive Officer of Rapid Bio; Kirill Kayem, Deputy Chairman of the Management Board for Priority Areas of Technological Development at the Skolkovo Foundation; and Evgeny Borisov, Partner at investment company KAMA FLOW.
The signing took place as part of the official business programme of SPIEF-2025, one of the largest international platforms for dialogue on economics, science and technology. The partners say the deal opens the way for new collaborations, new products and a broader contribution to public health in Russia and beyond.
Under the agreement, the parties plan to pool their efforts to support the growth of Rapid Bio as a technological leader in point-of-care and rapid diagnostic solutions, including assistance with scaling development and manufacturing of domestic products.
The memorandum was signed by Anzhey Zhimbiyev, Chief Executive Officer of Rapid Bio; Kirill Kayem, Deputy Chairman of the Management Board for Priority Areas of Technological Development at the Skolkovo Foundation; and Evgeny Borisov, Partner at investment company KAMA FLOW.
The signing took place as part of the official business programme of SPIEF-2025, one of the largest international platforms for dialogue on economics, science and technology. The partners say the deal opens the way for new collaborations, new products and a broader contribution to public health in Russia and beyond.